ACADIA Pharmaceuticals (ACAD) vs Xeris Biopharma (XERS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Xeris Biopharma (XERS) has outperformed ACADIA Pharmaceuticals (ACAD) over the past year, gaining 148.5% versus a loss of 27.4%. Over five years, XERS leads with a +682.0% price change compared with -8.9% for ACAD. Xeris Biopharma is the larger company by market cap ($3.10 billion vs $2.96 billion), about 1.0 times the size.
On valuation, ACADIA Pharmaceuticals trades at a lower forward P/E (15.8x vs 63.6x for Xeris Biopharma). ACADIA Pharmaceuticals converts more of its revenue into profit, with a net margin of 36.5% versus 0.2%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ACAD | XERS |
|---|---|---|
| Share price | $17.11 | $16.97 |
| Market cap | $2.96B | $3.10B |
| 1-day change | -2.73% | +2.11% |
| YTD return | -35.94% | +116.18% |
| 1-year return | -27.38% | +148.46% |
| 5-year return | -8.94% | +682.03% |
| P/E ratio (TTM) | 8.07 | — |
| Forward P/E | 15.75 | 63.64 |
| EPS (TTM) | $2.12 | $-0.03 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $1.07B | $291.85M |
| Revenue growth (YoY) | +11.87% | +43.72% |
| Net income (latest FY) | $391.00M | $554.00K |
| Gross margin | 91.69% | 85.41% |
| Operating margin | 9.78% | 8.53% |
| Net margin | 36.49% | 0.19% |
| 52-week high | $30.96 | $17.28 |
| 52-week low | $15.86 | $5.25 |
| Distance from 52-week high | -44.74% | -1.79% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +77.21% | +1.89% |
| Average volume | 2.18M | 2.86M |
| Shares outstanding | 172.83M | 182.70M |
| Employees | 796 | 435 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- XERS has outperformed ACAD by 175.8 percentage points over the past year.
- ACADIA Pharmaceuticals is more profitable, keeping 36.5 cents of every revenue dollar as net income versus 0.2 cents for Xeris Biopharma.
- Xeris Biopharma grew revenue faster in its latest fiscal year (+43.72% vs +11.87%).
About ACADIA Pharmaceuticals
ACAD stock →ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for neurological and rare disease in North America. The company offers NUPLAZID (pimavanserin), a selective serotonin inverse agonist/antagonist for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 to treat the symptoms of Rett syndrome by reducing neuroinflammation and supporting synaptic function.
Health Care · Biotechnology: Pharmaceutical Preparations · 796 employees
About Xeris Biopharma
XERS stock →Xeris Biopharma Holdings, Inc., a commercial-stage biopharmaceutical company, engages in developing and commercializing therapies for chronic endocrine and neurological diseases in Illinois. It offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia in pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.
Health Care · Biotechnology: Pharmaceutical Preparations · 435 employees
ACAD vs XERS FAQ
Which is bigger, ACADIA Pharmaceuticals or Xeris Biopharma?
Xeris Biopharma (XERS) is larger, with a market capitalization of $3.10B compared with $2.96B for ACADIA Pharmaceuticals (ACAD).
Which stock has performed better over the past year, ACAD or XERS?
XERS returned +148.46% over the past 12 months, compared with -27.38% for ACAD (price return, excluding dividends). Past performance does not predict future results.
Are ACADIA Pharmaceuticals and Xeris Biopharma in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.